ISSN : 0975-9492


Open Access

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information:
verify here.


Title : The genetic basis of the clinical diversity of the Trans-Resveratrol therapy in beta-thalassemic and sickle cell anaemia patients
Authors : Anirban Roy Chowdhury, Sudipa Chakravarty, Amit Chakravarty
Keywords : Resveratrol, -thalassemia, HbF , Blood transfusion, Good responder, Moderate responder, Nonresponder.
Issue Date : Oct 2017
Abstract :
Trans-Resveratrol responses were influenced by Several genetic, non-genetic and pharmacological factors in different early studies. The response to Trans-Resveratrol is significantly different among good, moderate and non-responders irrespective of the IVS I-5 (G?C), the common beta mutation here and even among other 0 or + thalassaemia mutations. It has been shown that even among good responders in some cases (8.39 %) patients are not showing high HbF values. ( < 20% HbF values are taken). We studied among 220 patients that Trans-Resveratrol therapy completely replace blood transfusion in Eastern part of India. The predominant -thalassemia defect is the IVSI-5(G?C), the most frequent 0- thal mutation in the area. This mutation is found in 87.66% of the CR patients and in 86.66% of the PR / NR patients. The next represented defects are the +-thalassemia mutations like Cod 8/9, Fr. 41/42, Cod 15, Cod 30 etc. The distribution of the IVSI-5 (G?C) genotype among the CR, PR / NR. The common IVSI-5 (G?C) mutation in beta thalassemia patients (either in homozygous or heterozygous form) is present in 31.5% among the good responders (CR) while it is present in 66.66% among PR / NR ( moderate responders / non-responders) and in HbE-beta patients present in 73.28% among good responders (CR) while in 33.33% among moderate / non responders (PR / NR).
Page(s) : 211-214
ISSN : 0975-9492
Source : Vol. 8, No.11